Ra Capital Management, L.P. Cerevel Therapeutics Holdings, Inc. Transaction History

Ra Capital Management, L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 15, 2021	SELL	$21.26 - $38.85 $46.8 Million - $85.5 Million	-2,200,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $21.6 Million - $40.2 Million	2,200,000 New	2,200,000 $36.5 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.